Yahoo Finance 4 Stocks Providing Investor Opportunity Right Now
CORAL GABLES, FL / ACCESSWIRE / December 17, 2018 / 2018 and its wild market swings are winding down as 2019 gears up. This week investors are being presented with several stocks providing volatile upside swings.
On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest. This morning Monday 12/17/2018 the company announced it has signed a binding LOI to acquire all the outstanding securities of Cloud Practice Inc.
Key points of the deal focus on Cloud's product portfolio, which includes Juno EMR, a cloud-based EMR solution; ClinicAid, a medical billing software, and MyHealthAccess, an online patient portal. Juno EMR system is currently used by 287 clinics, over 3,000 licensed practitioners, 1,500 staff and 2,870,000 registered patients. In addition, ClinicAid processes upwards of $30,000,000 in payments to over 3000 health providers on a monthly basis.
Last week Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) signed another binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy. For the fiscal year 2017/18, the pharmacy reported revenues of approximately $1MM and Adjusted EBITDA of approximately 30% according to Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI).
For More Information On Premier Health Group, Click Here
Diffusion Pharmaceuticals Inc. (DFFN) announced a 1 for 15 reverse split last week and on Monday, shares not only reflected the new price but were off to a running start at the opening bell. On Monday the company announced that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate, in conjunction with Tissue Plasminogen Activator for the treatment of stroke.
Diffusion's lead drug, Trans Sodium Crocetinate, was originally developed in conjunction with the Office of Naval Research, which was seeking a way to treat hemorrhagic shock caused by massive blood loss on the battlefield.
Diffusion shares reached highs of $5.13 during the first hour of trading on Monday and as of the time of this writing, still trade near $4 per share.
For More Information On Diffusion Pharma, Click Here
Evofem Biosciences, Inc. (EVFM) shares were also trading higher on Monday. Following a close of $3.54 on Friday, Evofem jumped as high as $5.37 during premarket trading this morning. This followed the company's latest announcement that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint.
The company said it plans to resubmit the marketing application for Amphora in the second quarter next year and approval could make it the first non-hormonal birth control vaginal gel. "We are excited by these compelling study results, which solidify Amphora's position as the most substantial birth control innovation in nearly 20 years and a significant advancement for women and their sexual and reproductive health," said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences.
For More Information On Evofem, Click Here
Synergy Pharmaceuticals Inc. (SGYP) was in the news today when Cipher Pharmaceuticals Inc. announced that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation has been accepted by Health Canada. Where Synergy comes into play is that it was the company that Cipher acquired TRULANCE from earlier this year.
The drug is a once-daily tablet approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adults with IBS-C. Synergy has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders.
For More Information On Synergy Pharmaceuticals, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com
